{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T11:08:41Z","timestamp":1772795321367,"version":"3.50.1"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T00:00:00Z","timestamp":1649721600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.ebiom.2022.104025","type":"journal-article","created":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T07:59:38Z","timestamp":1651823978000},"page":"104025","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Analysis of a SARS-CoV-2 convalescent cohort identified a common strategy for escape of vaccine-induced anti-RBD antibodies by Beta and Omicron variants"],"prefix":"10.1016","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7244-997X","authenticated-orcid":false,"given":"Matthew R.","family":"Chang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanzhong","family":"Ke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian D.","family":"Coherd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yufei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4736-3285","authenticated-orcid":false,"given":"Kiyomi","family":"Mashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriella M.","family":"Kastrunes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiung-Yu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wayne A.","family":"Marasco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ebiom.2022.104025_bib0001","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.molcel.2020.07.027","article-title":"Coronavirus RNA proofreading: molecular basis and therapeutic targeting","volume":"79","author":"Robson","year":"2020","journal-title":"Mol Cell"},{"key":"10.1016\/j.ebiom.2022.104025_bib0002","doi-asserted-by":"crossref","first-page":"5212","DOI":"10.1016\/j.jmb.2020.07.009","article-title":"Mutations strengthened SARS-CoV-2 infectivity","volume":"432","author":"Chen","year":"2020","journal-title":"J Mol Biol"},{"key":"10.1016\/j.ebiom.2022.104025_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.meegid.2021.104897","article-title":"Paired SARS-CoV-2 spike protein mutations observed during ongoing SARS-CoV-2 viral transfer from humans to minks and back to humans","volume":"93","author":"Burkholz","year":"2021","journal-title":"Infect Genet Evol"},{"key":"10.1016\/j.ebiom.2022.104025_bib0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-021-91662-w","article-title":"Concurrent mutations in RNA-dependent RNA polymerase and spike protein emerged as the epidemiologically most successful SARS-CoV-2 variant","volume":"11","author":"Ilmj\u00e4rv","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.ebiom.2022.104025_bib0005","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00617-21","article-title":"V367F mutation in SARS-CoV-2 spike RBD emerging during the early transmission phase enhances viral infectivity through increased human ACE2 receptor binding affinity","volume":"95","author":"Ou","year":"2021","journal-title":"J Virol"},{"key":"10.1016\/j.ebiom.2022.104025_bib0006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/Spectrum.00261-21","article-title":"SARS-CoV-2 quasispecies provides an advantage mutation pool for the epidemic variants","volume":"9","author":"Sun","year":"2021","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.ebiom.2022.104025_bib0007","article-title":"Omicron and Delta variant of SARS-CoV-2: a comparative computational study of spike protein","author":"Kumar","year":"2021","journal-title":"J Med Virol"},{"key":"10.1016\/j.ebiom.2022.104025_bib0008","article-title":"Improved neutralization of the SARS-CoV-2 Omicron variant after Pfizer-BioNTech BNT162b2 COVID-19 vaccine boosting","author":"Basile","year":"2021","journal-title":"BioRxiv"},{"key":"10.1016\/j.ebiom.2022.104025_bib0009","first-page":"2008","article-title":"Third BNT162b2 Vaccination neutralization of SARS-CoV-2 Omicron infection","author":"Nemet","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2022.104025_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2021.12.033","article-title":"mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant","author":"Garcia-Beltran","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.ebiom.2022.104025_bib0011","first-page":"2008","article-title":"Plasma neutralization of the SARS-CoV-2 Omicron variant","author":"Schmidt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2022.104025_bib0012","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/s41586-021-04005-0","article-title":"High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape","volume":"600","author":"Schmidt","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ebiom.2022.104025_bib0013","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1126\/science.abg9175","article-title":"mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection","volume":"372","author":"Stamatatos","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.ebiom.2022.104025_bib0014","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1126\/science.abj2258","article-title":"Hybrid immunity","volume":"372","author":"Crotty","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.ebiom.2022.104025_bib0015","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1038\/s41564-020-00813-8","article-title":"Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans","volume":"5","author":"Seow","year":"2020","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.ebiom.2022.104025_bib0016","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ejim.2021.05.010","article-title":"SARS-CoV-2 antibody kinetics eight months from COVID-19 onset: persistence of spike antibodies but loss of neutralizing antibodies in 24% of convalescent plasma donors","volume":"89","author":"Terpos","year":"2021","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.ebiom.2022.104025_bib0017","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1056\/NEJMc2025179","article-title":"Rapid decay of anti\u2013SARS-CoV-2 antibodies in persons with mild Covid-19","volume":"383","author":"Ibarrondo","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2022.104025_bib0018","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1093\/infdis\/jiaa659","article-title":"Longitudinal serological analysis and neutralizing antibody levels in coronavirus disease 2019 convalescent patients","volume":"223","author":"Muecksch","year":"2021","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ebiom.2022.104025_bib67","doi-asserted-by":"crossref","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"key":"10.1016\/j.ebiom.2022.104025_bib68","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"10.1016\/j.ebiom.2022.104025_bib0019","unstructured":"Hodcroft E.B. CoVariants: SARS-CoV-2 mutations and variants of interest 2021. https:\/\/covariants.org\/."},{"key":"10.1016\/j.ebiom.2022.104025_bib0020","article-title":"Four SARS-CoV-2 vaccines induce quantitatively different antibody responses against SARS-CoV-2 variants","author":"van Gils","year":"2021","journal-title":"MedRxiv"},{"key":"10.1016\/j.ebiom.2022.104025_bib0021","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-021-04386-2","article-title":"Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift","author":"Cameroni","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ebiom.2022.104025_bib0022","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/s41586-021-03402-9","article-title":"Detection of a SARS-CoV-2 variant of concern in South Africa","volume":"592","author":"Tegally","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ebiom.2022.104025_bib0023","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41586-021-03324-6","article-title":"mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants","volume":"592","author":"Wang","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ebiom.2022.104025_bib0024","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.abf1906","article-title":"The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates","volume":"13","author":"Jones","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ebiom.2022.104025_bib0025","article-title":"Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016","volume":"2","author":"Starr","year":"2021","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.ebiom.2022.104025_bib0026","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1126\/science.abd0827","article-title":"Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail","volume":"369","author":"Hansen","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ebiom.2022.104025_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.103341","article-title":"Partial resistance of SARS-CoV-2 Delta variants to vaccine-elicited antibodies and convalescent sera","volume":"24","author":"Tada","year":"2021","journal-title":"IScience"},{"key":"10.1016\/j.ebiom.2022.104025_bib0028","doi-asserted-by":"crossref","first-page":"5432","DOI":"10.1016\/j.cell.2021.09.015","article-title":"Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines","volume":"184","author":"Walls","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.ebiom.2022.104025_bib0029","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1056\/NEJMc2102179","article-title":"Serum neutralizing activity elicited by mRNA-1273 vaccine","volume":"384","author":"Wu","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2022.104025_bib0030","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/s41586-021-03412-7","article-title":"Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies","volume":"593","author":"Collier","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ebiom.2022.104025_bib0031","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.cell.2020.08.012","article-title":"Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding","volume":"182","author":"Starr","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ebiom.2022.104025_bib0032","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-022-04399-5","article-title":"Activity of convalescent and vaccine serum against a B.1.1.529 variant SARS-CoV-2 isolate","author":"Carre\u00f1o","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ebiom.2022.104025_bib0033","first-page":"1","article-title":"Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients","author":"Lu","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ebiom.2022.104025_bib0034","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1056\/NEJMc2115596","article-title":"Differential kinetics of immune responses elicited by Covid-19 vaccines","volume":"385","author":"Collier","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2022.104025_bib0035","doi-asserted-by":"crossref","DOI":"10.1126\/science.abi6226","article-title":"Effect of natural mutations of SARS-CoV-2 on spike structure, conformation, and antigenicity","volume":"373","author":"Gobeil","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.ebiom.2022.104025_bib0036","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7554\/eLife.70658","article-title":"Effects of common mutations in the SARS-CoV-2 spike RBD and its ligand the human ACE2 receptor on binding affinity and kinetics","volume":"10","author":"Barton","year":"2021","journal-title":"Elife"},{"key":"10.1016\/j.ebiom.2022.104025_bib0037","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-24435-8","article-title":"Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies","volume":"12","author":"Greaney","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.ebiom.2022.104025_bib0038","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-021-01081-0","article-title":"Molecular strategies for antibody binding and escape of SARS-CoV-2 and its mutations","volume":"11","author":"Hendy","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.ebiom.2022.104025_bib0039","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/j.cell.2021.03.013","article-title":"Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity","volume":"184","author":"Garcia-Beltran","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.ebiom.2022.104025_bib0040","doi-asserted-by":"crossref","first-page":"e2693","DOI":"10.1002\/jmr.2693","article-title":"Local and global anatomy of antibody-protein antigen recognition","volume":"31","author":"Wang","year":"2018","journal-title":"J Mol Recognit"},{"key":"10.1016\/j.ebiom.2022.104025_bib0041","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/19420862.2021.1919285","article-title":"501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to bamlanivimab in vitro","volume":"13","author":"Liu","year":"2021","journal-title":"MAbs"},{"key":"10.1016\/j.ebiom.2022.104025_bib0042","first-page":"1","article-title":"Antibodies elicited by SARS-CoV-2 infection or mRNA vaccines have reduced neutralizing activity against Beta and Omicron pseudoviruses","volume":"7842","author":"Sievers","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ebiom.2022.104025_bib0043","unstructured":"GeurtsvanKessel CH, Geers D, Schmitz KS, et\u00a0al. Divergent SARS CoV-2 Omicron-specific T- and B-cell responses in COVID-19 vaccine recipients. MedRxiv 2021;2202:2021.12.27.21268416."},{"key":"10.1016\/j.ebiom.2022.104025_bib0044","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/s41586-020-2548-6","article-title":"Potently neutralizing and protective human antibodies against SARS-CoV-2","volume":"584","author":"Zost","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ebiom.2022.104025_bib0045","article-title":"SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection","author":"Cele","year":"2021","journal-title":"MedRxiv Prepr Serv Heal Sci"},{"key":"10.1016\/j.ebiom.2022.104025_bib0046","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1126\/science.aag1322","article-title":"Potent protection against H5N1 and H7N9 influenza via childhood hemagglutinin imprinting","volume":"354","author":"Gostic","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.ebiom.2022.104025_bib0047","article-title":"SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses","author":"Dejnirattisai","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.ebiom.2022.104025_bib0048","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1056\/NEJMc2114706","article-title":"Neutralization of the SARS-CoV-2 Mu variant by convalescent and vaccine serum","volume":"385","author":"Uriu","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2022.104025_bib0049","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-021-00777-9","article-title":"Antibody cocktail effective against variants of SARS-CoV-2","volume":"28","author":"Liang","year":"2021","journal-title":"J Biomed Sci"},{"key":"10.1016\/j.ebiom.2022.104025_bib0050","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s41586-020-2852-1","article-title":"SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies","volume":"588","author":"Barnes","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ebiom.2022.104025_bib0051","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.cell.2020.06.025","article-title":"Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies","volume":"182","author":"Barnes","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ebiom.2022.104025_bib0052","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1126\/science.abc2241","article-title":"A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2","volume":"368","author":"Wu","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ebiom.2022.104025_bib0053","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1126\/science.abd2321","article-title":"Structural basis of a shared antibody response to SARS-CoV-2","volume":"369","author":"Yuan","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ebiom.2022.104025_bib0054","article-title":"The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants","author":"Liu","year":"2021","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.ebiom.2022.104025_bib0055","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1016\/j.cell.2021.02.032","article-title":"The antigenic anatomy of SARS-CoV-2 receptor binding domain","volume":"184","author":"Dejnirattisai","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.ebiom.2022.104025_bib0056","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.str.2021.05.014","article-title":"Structural basis for accommodation of emerging B.1.351 and B.1.1.7 variants by two potent SARS-CoV-2 neutralizing antibodies","volume":"29","author":"Cerutti","year":"2021","journal-title":"Structure"},{"key":"10.1016\/j.ebiom.2022.104025_bib0057","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.09.035","article-title":"Structurally resolved SARS-CoV-2 antibody shows high efficacy in severely infected hamsters and provides a potent cocktail pairing strategy","author":"Du","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ebiom.2022.104025_bib0058","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1126\/science.abd0827","article-title":"Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail","volume":"369","author":"Hansen","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ebiom.2022.104025_bib0059","unstructured":"Westendorf K, \u017dentelis S, Foster D, et\u00a0al. LY-CoV1404 potently neutralizes SARS-CoV-2 variants. BioRxiv Prepr Serv Biol 2021:2021.04.30.442182. 10.1101\/2021.04.30.442182."},{"key":"10.1016\/j.ebiom.2022.104025_bib0060","first-page":"eabe3354","article-title":"Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms","volume":"957","author":"Tortorici","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ebiom.2022.104025_bib0061","series-title":"SARS-CoV-2 RBD antibodies that Maximize Breadth and Resistance to Escape","author":"Starr","year":"2021"},{"key":"10.1016\/j.ebiom.2022.104025_bib0062","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41586-021-03817-4","article-title":"Broad sarbecovirus neutralization by a human monoclonal antibody","volume":"597","author":"Tortorici","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ebiom.2022.104025_bib0063","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009089","article-title":"A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody","volume":"16","author":"Wu","year":"2020","journal-title":"PLOS Pathog"},{"key":"10.1016\/j.ebiom.2022.104025_bib0064","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109760","article-title":"Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies","volume":"36","author":"Jette","year":"2021","journal-title":"Cell Rep"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396422002092?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396422002092?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T19:15:45Z","timestamp":1762456545000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396422002092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":66,"alternative-id":["S2352396422002092"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2022.104025","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analysis of a SARS-CoV-2 convalescent cohort identified a common strategy for escape of vaccine-induced anti-RBD antibodies by Beta and Omicron variants","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2022.104025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104025"}}